Get the Stockscreener App
9.245
2.15%
0.195
After Hours:
9.29
0.045
+0.49%
Aurinia Pharmaceuticals Inc stock is traded at $9.245, with a volume of 5.56M.
It is up +2.15% in the last 24 hours and up +9.15% over the past month.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
See More
Previous Close:
$9.05
Open:
$9.1
24h Volume:
5.56M
Relative Volume:
3.64
Market Cap:
$1.25B
Revenue:
$175.51M
Net Income/Loss:
$-78.02M
P/E Ratio:
-17.44
EPS:
-0.53
Net Cash Flow:
$-34.18M
1W Performance:
+1.93%
1M Performance:
+9.15%
6M Performance:
+16.29%
1Y Performance:
+57.23%
1-Day Range:
$8.85
$9.83
1-Week Range:
$8.80
$9.83
52-Week Range:
$5.195
$10.67
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Name
Aurinia Pharmaceuticals Inc
Sector
Industry
Phone
250-744-2487
Address
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
9.245 | 1.22B | 175.51M | -78.02M | -34.18M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | H.C. Wainwright | Buy |
| Nov-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| May-05-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-28-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-25-21 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| May-05-20 | Initiated | Cowen | Outperform |
| Jan-10-20 | Initiated | Jefferies | Buy |
| Dec-16-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-16-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-30-17 | Reiterated | H.C. Wainwright | Buy |
| May-18-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-22-17 | Reiterated | FBR & Co. | Outperform |
| Dec-30-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-17-16 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-16 | Initiated | H.C. Wainwright | Buy |
| May-08-15 | Initiated | MLV & Co | Buy |
View All
Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News
Aurinia (AUPH) Q2 Revenue Jumps 22% - The Globe and Mail
Aurinia raises 2025 revenue outlook to $270M as LUPKYNIS accelerates market penetration - MSN
Contradictions in LUPKYNIS and AUR200: Insights from the Latest Earnings Call - AInvest
Aurinia: Q2 Earnings Snapshot - CTPost
What catalysts could drive Aurinia Pharmaceuticals Inc. stock higher in 2025Post Market Opportunities With High Returns - jammulinksnews.com
Aurinia Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Aurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates - Yahoo Finance
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025 - BioSpace
Aurinia Pharmaceuticals' Strong Q2 2025 Performance and Strategic Share Repurchases: A Compelling Buy Opportunity for Long-Term Growth - AInvest
Aurinia Pharmaceuticals tops Q2 estimates, raises full-year guidance - Investing.com Australia
Aurinia Pharma earnings beat by $0.02, revenue topped estimates - Investing.com Canada
Aurinia Pharmaceuticals Inc. SEC 10-Q Report - TradingView
Aurinia Pharmaceuticals Reports Strong Q2 2025 Financial Results and Expands Share Repurchase Plan - TipRanks
H.C. Wainwright assumes coverage on Aurinia Pharmaceuticals stock with Buy rating - Investing.com
Published on: 2025-07-29 10:22:20 - metal.it
Should I hold or sell Aurinia Pharmaceuticals Inc. stock in 2025Superior investment outcomes - jammulinksnews.com
What makes Aurinia Pharmaceuticals Inc. stock price move sharplyEarnings Report Picks With High Returns - jammulinksnews.com
Does Aurinia Pharmaceuticals Inc. stock perform well during market downturnsSuperior portfolio returns - jammulinksnews.com
What is Aurinia Pharmaceuticals Inc. company’s growth strategyAchieve breakthrough profits with expert advice - jammulinksnews.com
Why is Aurinia Pharmaceuticals Inc. stock attracting strong analyst attentionMaximize your portfolio’s earning power - jammulinksnews.com
Is Aurinia Pharmaceuticals Inc. a growth stock or a value stockRapid market gains - jammulinksnews.com
What is the risk reward ratio of investing in Aurinia Pharmaceuticals Inc. stockGet professional advice for market timing - jammulinksnews.com
Is Aurinia Pharmaceuticals Inc. Stock a Smart Buy in 2025 Investment Analysis InsideWatchlist Winner Update - metal.it
Can Aurinia Pharmaceuticals Inc. stock recover from recent declineSafe and Smart Investment Picks - metal.it
Aurinia Pharmaceuticals Inc. Stock Analysis and ForecastFastest-growing stock picks - PrintWeekIndia
Will Aurinia Pharmaceuticals Inc. stock split in the near futureMarket-leading growth rates - jammulinksnews.com
What analysts say about Aurinia Pharmaceuticals Inc. stockRapid growth opportunities - Autocar Professional
When is the best time to buy Aurinia Pharmaceuticals Inc. stockSuperior profit margins - jammulinksnews.com
Is Aurinia Pharmaceuticals Inc. a good long term investmentTremendous gains - PrintWeekIndia
What drives Aurinia Pharmaceuticals Inc. stock priceUnmatched profit growth - Autocar Professional
Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025 - Zenopa
Aurinia Pharmaceuticals to Announce Q2 2025 Financial Results - The Globe and Mail
Aurinia Pharmaceuticals: LUPKYNIS Growth and AUR200 Pipeline Fuel Long-Term Value - AInvest
ISS Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting - Yahoo.co
Aurinia Pharmaceuticals Inc Stock (AUPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):